Martina Lambertini, MD, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Via Massarenti, 1 - 40138 Bologna, Italy;
Acta Dermatovenerol Croat. 2023 Nov;31(2):98-100.
Dear Editor, Actinic keratoses (AK) have a high prevalence in the general population, with greater rates in Caucasian patients after the fourth and fifth decades of life (37.5-60.0%) (1,2). Standard histopathologic reporting of AKs does not provide information on the presence of atypical keratinocytes extending to the hair follicle, also defined as folliculotropism (FLC). Commonly, atypical cells in AKs do not present FLC, but this feature can be observed in bowenoid AKs with full-thickness epidermal atypia (3,4). FLC has been considered a possible element enhancing the chances of a progression toward invasive SCC (iSCC). Fernandez-Figueras et al. (3) reported that the depth of FLC in AKs was correlated with the invasiveness of associated iSCC. Pandey et al. (5) reported a positive association between AKs with FLC and history of invasive cutaneous cancer or melanoma, more often in men at an older age. The role of FLC in cutaneous melanoma is still debated, but it is considered a parameter that may correlate with treatment response in lentigo maligna and disease progression or recurrences in invasive tumors (6,7). These studies draw particular attention to the potential role of hair bulge compartment stem cells in favoring tumor progression through the expression of adhesion molecules, cytokines, and growth factor receptors (8). Aks are known to have a high recurrence rate after topical treatment (1). The risk of evolution to an iSCC is not completely clear, but it has been estimated to be around 0.6% at 12 months and up to 2.5% at 48 months (1,3,7). Considering the possible progression and the heavy burden of AK treatments, including the economic burden, it is imperative to focus on histopathologic features associated with treatment failure. The aim of this preliminary study was to assess the histopathologic features, specifically FLC, of AK samples from patients considered "non-responders" to specific topical treatments. A secondary endpoint was to assess the clinical/dermoscopic features. Patients were considered "non-responders" if the lesions persisted after two alternated completed cycles of treatments with ingenol mebutate, imiquimod, diclofenac 3%, or 5-fluoruracil. Patients with a positive history of immunosuppression or genetic diseases were excluded. The study was approved by the local Ethics Committee. Slides of AKs diagnosed at the Laboratory of Dermatopathology, University of Bologna, Italy from January 2016 to October 2018 were reviewed by two dermatopathologists (CM, PAF). 155 "non-responder" AKs of five main histopathologic subtypes were included, classified from grade I to III according to the Roewert-Huber classification (9) (Table 1). The proliferative and atrophic histopathologic subtypes of AKs were detected in 33.6% and 30.4% samples, respectively. FLC was observed in 75.3% of the cases, subdivided into two categories, periadnexal (48.9%) and intraadnexal (26.4%). Periadnexal FLC was detected in 31.0% of atrophic and in 50.3% of proliferative AKs, while intraadnexal FLC was found in 48.7% and 29.2%, respectively (Figure 1, a, b). At dermoscopy, most lesions had been classified as grade I or II (38.8% and 45.8%), and only 15.4% as grade III, showing an unexpected non-response to treatment according to the dermoscopic criteria. In contrast, almost half of the AKs were classified as grade III at histology, revealing a discrepancy between the dermoscopic grading and histological findings in a majority of cases (77.4%) (Figure 2, c, d). Furthermore, atrophic and proliferative AKs accounted for 64.0% of total cases, and these are the variants associated with a higher probability of evolution toward an iSCC (10). The clinical/histological discrepancy has already been reported in the literature (9) and may represent a misleading factor for treatment choice and outcomes. We believe that a comparative analysis with dermoscopy and histology should be performed in non-responding AKs, in order to choose the best therapeutic option. In fact, some superficial treatments (such as cryotherapy) may not provide a good response in deep hair follicles (4). We also suggest encouraging greater focus on FLC and its description in pathology reports. This is a preliminary observational study, but it reinforces the need to further larger clinical studies investigating the role of specific histopathologic parameters in AKs, including FLC, that may correlate with treatment outcomes.
光化性角化病(AK)在普通人群中的患病率很高,在白种人患者中,发病率在第四和第五个十年更高(37.5-60.0%)(1,2)。AK 的标准组织病理学报告不提供有关延伸至毛囊的非典型角质形成细胞(也称为滤泡亲嗜性)存在的信息。通常,AK 中的非典型细胞不存在滤泡亲嗜性,但在具有全层表皮非典型性的鲍恩样 AK 中可以观察到(3,4)。滤泡亲嗜性已被认为是向侵袭性 SCC(iSCC)进展的可能性增强的一个因素。Fernández-Figueras 等人(3)报道,AK 中滤泡亲嗜性的深度与相关 iSCC 的侵袭性相关。Pandey 等人(5)报道,具有滤泡亲嗜性的 AK 与侵袭性皮肤癌或黑色素瘤的病史之间存在正相关,并且在年龄较大的男性中更为常见。滤泡亲嗜性在皮肤黑色素瘤中的作用仍存在争议,但它被认为是与光线性角化病的治疗反应相关的一个参数,并且与侵袭性肿瘤的疾病进展或复发相关(6,7)。这些研究特别关注毛囊球部干细胞在促进肿瘤进展中的潜在作用,这可能通过表达粘附分子、细胞因子和生长因子受体来实现(8)。AK 经局部治疗后复发率高(1)。向 iSCC 进展的风险尚不完全清楚,但据估计,在 12 个月时约为 0.6%,在 48 个月时高达 2.5%(1,3,7)。考虑到可能的进展和 AK 治疗的沉重负担,包括经济负担,因此必须关注与治疗失败相关的组织病理学特征。本初步研究的目的是评估被认为是特定局部治疗“无反应”的 AK 样本的组织病理学特征,特别是滤泡亲嗜性。次要终点是评估临床/皮肤镜特征。如果病变在交替完成两次 Ingenol mebutate、咪喹莫特、二氯芬酸 3%或 5-氟尿嘧啶治疗周期后仍持续存在,则将患者视为“无反应者”。排除有免疫抑制或遗传疾病病史的患者。该研究得到了当地伦理委员会的批准。意大利博洛尼亚大学皮肤科病理实验室从 2016 年 1 月至 2018 年 10 月诊断的 AK 切片由两位皮肤科病理学家(CM、PAF)进行了回顾。纳入了五个主要组织病理学亚型的 155 例“无反应”AK,根据 Roewert-Huber 分类(9)(表 1)将其分为 I 级至 III 级。AK 的增生性和萎缩性组织病理学亚型分别占 33.6%和 30.4%。在 75.3%的病例中观察到滤泡亲嗜性,分为周围型(48.9%)和内附型(26.4%)。在萎缩性和增生性 AK 中分别检测到 31.0%和 50.3%的周围型滤泡亲嗜性,而内附型分别为 48.7%和 29.2%(图 1,a,b)。在皮肤镜下,大多数病变被分类为 I 级或 II 级(38.8%和 45.8%),仅 15.4%为 III 级,这与皮肤镜标准显示的治疗反应不符。相反,在组织学上,几乎一半的 AK 被分类为 III 级,这表明在大多数情况下,皮肤镜分级与组织学发现之间存在差异(77.4%)(图 2,c,d)。此外,增生性和萎缩性 AK 占总病例的 64.0%,这是与向 iSCC 进展相关的可能性更高的变体(10)。文献中已经报道了临床/组织学差异(9),这可能是治疗选择和结果的误导因素。我们认为,应该对非反应性 AK 进行皮肤镜和组织学比较分析,以选择最佳的治疗方案。事实上,一些浅表治疗(如冷冻疗法)可能不能为深部毛囊提供良好的反应(4)。我们还建议鼓励更多地关注滤泡亲嗜性及其在病理学报告中的描述。这是一项初步的观察性研究,但它进一步强调了需要进行更大的临床研究,以调查 AK 中包括滤泡亲嗜性在内的特定组织病理学参数的作用,这些参数可能与治疗结果相关。